RESUMO
BACKGROUND: To determine the association of vancomycin with acute kidney injury (AKI) in relation to its serum concentration value and to examine the risk of AKI in patients treated with vancomycin when compared with a matched cohort of patients receiving non-glycopeptide antibiotics (linezolid/daptomycin). METHODS: From a cohort of > 3 million US veterans with baseline estimated glomerular filtration rate ≥60 mL/min/1.73 m2, we identified 33,527 patients who received either intravenous vancomycin (n = 22,057) or non-glycopeptide antibiotics (linezolid/daptomycin, n = 11,470). We examined the association of the serum trough vancomycin level recorded within the first 48 h of administration with subsequent AKI in all patients treated with vancomycin and association of vancomycin vs. non-glycopeptide antibiotics use with the risk of incident AKI. RESULTS: The overall multivariable adjusted ORs of AKI stages 1, 2, and 3 in patients on vancomycin vs. non-glycopeptides were 1.1 (1.1-1.2), 1.2 (1-1.4), and 1.4 (1.1-1.7), respectively. When examined in strata divided by vancomycin trough level, the odds of AKI were similar or lower in patients receiving vancomycin compared to non-glycopeptide antibiotics as long as serum vancomycin levels were ≤20 mg/L. However, in patients with serum vancomycin levels > 20 mg/L, the ORs of AKI stages 1, 2, and 3 in patients on vancomycin vs. non-glycopeptide antibiotics were 1.5 (1.4-1.7), 1.9 (1.5-2.3), and 2.7 (2-3.5), respectively. CONCLUSIONS: Vancomycin use is associated with a higher risk of AKI when serum levels exceed > 20 mg/L.
Assuntos
Injúria Renal Aguda/epidemiologia , Antibacterianos/efeitos adversos , Infecções Estafilocócicas/tratamento farmacológico , Vancomicina/efeitos adversos , Veteranos/estatística & dados numéricos , Injúria Renal Aguda/induzido quimicamente , Idoso , Antibacterianos/administração & dosagem , Antibacterianos/farmacocinética , Daptomicina/administração & dosagem , Daptomicina/efeitos adversos , Daptomicina/farmacocinética , Relação Dose-Resposta a Droga , Feminino , Taxa de Filtração Glomerular , Humanos , Linezolida/administração & dosagem , Linezolida/efeitos adversos , Linezolida/farmacocinética , Masculino , Staphylococcus aureus Resistente à Meticilina/isolamento & purificação , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Infecções Estafilocócicas/microbiologia , Estados Unidos , United States Department of Veterans Affairs/estatística & dados numéricos , Vancomicina/administração & dosagem , Vancomicina/farmacocinéticaRESUMO
Background: Prior small studies have suggested an association between low serum albumin and increased risk of venous thromboembolic (VTE) events in patients with nephrotic syndrome (NS). Methods: From a nationally representative prospective cohort of over 3 million US veterans with baseline estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m 2 , we identified 7037 patients with NS based on ICD-9 codes. Association between serum albumin and risk of incident VTE was assessed using Cox regression analysis with adjustments for age, gender, race, comorbidities, eGFR, body mass index and anticoagulant treatment. Results: Mean age was 57 ± 11 years, patients were 96% male, 32% African-American and 60% diabetic. There were a total of 158 VTE events over a median follow-up of 8.1 years; 16 events [absolute event rate (AER) 4.1%, event rate 8.5/1000 patient-years (PY)] in patients with albumin <2.5 g/dL, 18 events (AER 3.4%, event rate 5.7/1000 patient-years) in patients with albumin 2.5-2.99 g/dL, 89 events (AER 2.5%, event rate 3.4/1000 patient-years) in patients with albumin 3-3.99 g/dL and 35 events (AER 1.4%, event rate 1.9/1000 patient-years) in patients with albumin ≥4 g/dL. Compared with patients with albumin ≥4 g/dL, those with albumin levels of 3-3.99 g/dL [adjusted hazard ratio (HR): 1.51, 95% confidence interval (CI): 1.01-2.26], 2.5-2.99 g/dL (HR: 2.24, 95% CI: 1.24-4.05) and <2.5 g/dL (HR: 2.79, 95% CI: 1.45-5.37) experienced a linearly higher risk of VTE events. Conclusions: Lower serum albumin is a strong independent predictor for VTE events in NS. The risk increases proportionately with declining albumin levels. Clinical trials are needed to determine benefit of prophylactic anticoagulation in NS patients with moderately lower serum albumin levels.
Assuntos
Síndrome Nefrótica/complicações , Albumina Sérica/análise , Tromboembolia Venosa/sangue , Idoso , Anticoagulantes/uso terapêutico , Feminino , Taxa de Filtração Glomerular , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Fatores de Risco , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/tratamento farmacológico , Tromboembolia Venosa/etiologiaRESUMO
When encountering unusually appearing dialysate effluent from a patient doing peri- toneal dialysis, it is important to review the patient's recent exposures. In the case of "black"-appearing dialysate effluent, consideration needs to be given to the possibility of someone having undergone a colonoscopy and having tattooing with India ink. Nephrology nurses are frequently the first to be notified when there has been a change in the character of a patient's peritoneal dialysis dialysate effluent. This article describes a case of "black"-appearing dialysate and includes some of the potential differentials that were considered in the evaluation process. Even though "black"-appearing dialysate is a rare occurrence, nephrology nurses need to be aware of some of the potential etiologies, including exposure to India ink.
Assuntos
Líquido Ascítico/química , Carbono/efeitos adversos , Colonoscopia/efeitos adversos , Falência Renal Crônica/terapia , Peritônio/metabolismo , Peritonite/complicações , Tatuagem/efeitos adversos , Educação Continuada em Enfermagem , Humanos , Masculino , Pessoa de Meia-Idade , Peritonite/microbiologia , Diálise Renal/métodosRESUMO
Fibrillary glomerulopathy (FG) can occur either alone or co-existing with other proteinuric glomerular disorders. FG has been associated with poor renal outcomes leading to End Stage Renal Disease (ESRD). Since FG is a relatively rare disorder, limited information is available concerning treatment protocols. We present two patients with FG who were treated with rituximab after they had already progressed to stage 3 chronic kidney disease (CKD) with worsening proteinuria. Rituximab therapy resulted in long-term stabilization of renal function.
Assuntos
Anticorpos Monoclonais Murinos/uso terapêutico , Glomerulonefrite/tratamento farmacológico , Fatores Imunológicos/uso terapêutico , Glomérulos Renais/patologia , Glomerulonefrite/patologia , Humanos , Masculino , Pessoa de Meia-Idade , RituximabRESUMO
Importance: Inflammatory bowel disease (IBD) is associated with adverse clinical outcomes, including chronic kidney disease and mortality, due in part to chronic inflammation. Little is known about the effects of anti-tumor necrosis factor (TNF) therapy on kidney disease progression and mortality among patients with new-onset IBD. Objective: To examine the association of incident use of TNF inhibitors with subsequent decline in kidney function and risk of all-cause mortality. Design, Setting, and Participants: This retrospective cohort study used data from the US Department of Veterans Affairs health care system. Participants were US veterans with new-onset IBD enrolled from October 1, 2004, through September 30, 2019. Data were analyzed from December 2022 to February 2024. Exposures: Incident use of TNF inhibitors. Main Outcomes and Measures: The main outcomes were at least 30% decline in estimated glomerular filtration rate (eGFR) and all-cause mortality. Results: Among 10â¯689 patients (mean [SD] age, 67.4 [12.3] years; 9999 [93.5%] male) with incident IBD, 3353 (31.4%) had diabetes, the mean (SD) baseline eGFR was 77.2 (19.2) mL/min/1.73 m2, and 1515 (14.2%) were newly initiated on anti-TNF therapy. During a median (IQR) follow-up of 4.1 (1.9-7.0) years, 3367 patients experienced at least 30% decline in eGFR, and over a median (IQR) follow-up of 5.0 (2.5-8.0) years, 2502 patients died. After multivariable adjustments, incident use (vs nonuse) of TNF inhibitors was significantly associated with higher risk of decline in eGFR (adjusted hazard ratio [HR], 1.34 [95% CI, 1.18-1.52]) but was not associated with risk of all-cause mortality (adjusted HR, 1.02 [95% CI, 0.86-1.21]). Similar results were observed in sensitivity analyses. Conclusions and Relevance: In this cohort study of US veterans with incident IBD, incident use (vs nonuse) of TNF inhibitors was independently associated with higher risk of progressive eGFR decline but was not associated with risk of all-cause mortality. Further studies are needed to elucidate potentially distinct pathophysiologic contributions of TNF inhibitor use to kidney and nonkidney outcomes in patients with IBD.
Assuntos
Doenças Inflamatórias Intestinais , Inibidores do Fator de Necrose Tumoral , Idoso , Feminino , Humanos , Masculino , Estudos de Coortes , Doenças Inflamatórias Intestinais/tratamento farmacológico , Rim , Necrose , Estudos Retrospectivos , Inibidores do Fator de Necrose Tumoral/efeitos adversos , Inibidores do Fator de Necrose Tumoral/uso terapêuticoRESUMO
Kidney disease and pregnancy may exist in two general settings: acute kidney injury that develops during pregnancy, and chronic kidney disease that predates conception. In the first trimester of pregnancy, acute kidney injury is most often the result of hyperemesis gravidarum, ectopic pregnancy, or miscarriage. In the second and third trimesters, the common causes of acute kidney injury are severe preeclampsia, hemolysis-elevated liver enzymes-low platelets syndrome, acute fatty liver of pregnancy, and thrombotic microangiopathies, which may pose diagnostic challenges to the clinician. Cortical necrosis and obstructive uropathy are other conditions that may lead to acute kidney injury in these trimesters. Early recognition of these disorders is essential to timely treatment that can improve both maternal and fetal outcomes. In women with preexisting kidney disease, pregnancy-related outcomes depend upon the degree of renal impairment, the amount of proteinuria, and the severity of hypertension. Neonatal and maternal outcomes in pregnancies among renal transplant patients are generally good if the mother has normal baseline allograft function. Common renally active drugs and immunosuppressant medications must be prescribed, with special considerations in pregnant patients.
Assuntos
Nefropatias/complicações , Complicações na Gravidez/diagnóstico , Injúria Renal Aguda/complicações , Injúria Renal Aguda/diagnóstico , Injúria Renal Aguda/terapia , Nefropatias Diabéticas/complicações , Nefropatias Diabéticas/diagnóstico , Nefropatias Diabéticas/terapia , Feminino , Síndrome HELLP/diagnóstico , Síndrome HELLP/terapia , Humanos , Nefropatias/diagnóstico , Nefropatias/terapia , Transplante de Rim , Pré-Eclâmpsia/diagnóstico , Pré-Eclâmpsia/terapia , Gravidez , Complicações na Gravidez/terapia , Resultado da GravidezRESUMO
Progressive elevations of fibroblastic growth factor 23 (FGF23) in chronic kidney disease may reduce serum 25-hydroxyvitamin D (25(OH)) and 1,25-dihydroxyvitamin D (1,25(OH)(2)D) levels, via stimulation of 24-hydroxylase (Cyp24a1)-mediated catabolism of these vitamin D metabolites. To test this possibility, we measured serum concentrations of 24,25-dihydroxyvitamin D (24,25(OH)(2)D), a product of Cyp24a1 hydroxylation of 25(OH)D, in the Col4a3 knockout mouse, a model of Alport syndrome-derived chronic kidney disease, and in patients with chronic kidney disease of variable severity. There was an inverse correlation between serum FGF23 and both 25(OH)D and 1,25(OH)(2)D in the mouse model, but no significant relationship was observed in the cross-sectional patient cohort. The FGF23-dependent increase in Cyp24a1 mRNA expression in the mouse kidneys was consistent with the possibility that FGF23 induces vitamin D catabolism. There was, however, a reduction in serum 24,25(OH)(2)D levels, rather than the expected elevation, in both the mice and patients with chronic kidney disease. Low 25(OH)D and elevated FGF23 and parathyroid hormone levels were correlated with the reduced serum 24,25(OH)(2)D concentrations of these patients. Thus, we failed to find support for FGF23-mediated catabolism of vitamin D metabolites in chronic kidney disease assessed by 24,25(OH)(2)D levels.
Assuntos
Di-Hidroxicolecalciferóis/sangue , Fatores de Crescimento de Fibroblastos/sangue , Nefrite Hereditária/sangue , Insuficiência Renal Crônica/sangue , 25-Hidroxivitamina D3 1-alfa-Hidroxilase/metabolismo , Idoso , Animais , Autoantígenos/genética , Biomarcadores/sangue , Distribuição de Qui-Quadrado , Colágeno Tipo IV/deficiência , Colágeno Tipo IV/genética , Estudos Transversais , Modelos Animais de Doenças , Regulação para Baixo , Feminino , Fator de Crescimento de Fibroblastos 23 , Humanos , Hidroxilação , Rim/enzimologia , Masculino , Camundongos , Camundongos Knockout , Pessoa de Meia-Idade , Nefrite Hereditária/enzimologia , Hormônio Paratireóideo/sangue , RNA Mensageiro/metabolismo , Insuficiência Renal Crônica/enzimologia , Índice de Gravidade de Doença , Esteroide Hidroxilases/genética , Esteroide Hidroxilases/metabolismo , Regulação para Cima , Vitamina D/análogos & derivados , Vitamina D/sangue , Vitamina D3 24-HidroxilaseRESUMO
INTRODUCTION: Abnormal phosphorus homeostasis develops early in chronic kidney disease (CKD). It is unclear if its correction results in improved clinical outcomes in non-dialysis dependent CKD. METHODS: We conducted a randomized controlled, parallel design clinical trial in 120 patients with estimated glomerular filtration rate 15 to 59 ml/min per 1.73 m2 and abnormal phosphorus homeostasis (serum phosphorus >4.6 mg/dl, parathyroid hormone [PTH] >70 pg/ml or tubular reabsorption of phosphorus [TRP] <80%). Patients were randomized to open-label lanthanum carbonate versus calcium acetate versus dietary intervention over 1 year. The co-primary outcomes were month 12 (vs. baseline) biochemical (serum phosphorus, TRP, PTH, calcium, bone-specific alkaline phosphatase [bALP], and fibroblast growth factor 23 [FGF23]) and vascular parameters (coronary artery calcium score, pulse wave velocity, and endothelial dysfunction) in all patients. Secondary outcomes were between-treatment differences in change for each parameter between month 12 and baseline. All analyses were intention to treat. RESULTS: Baseline characteristics were similar in the 3 groups. A total of 107 patients (89%) completed 12 months of follow-up. Differences were not significant at month 12 (vs. baseline) for any of the outcomes except bALP (median [25th, 75th] percentile at month 12 versus baseline: 13.8 [10.6, 17.6] vs. 15.8 [12.1, 21.1], P < .001) and FGF23 (132 [99, 216] vs. 133 [86, 189], P = .002). Changes for all outcomes were similar in the 3 arms except for PTH, which was suppressed more effectively by calcium acetate (P < .001). CONCLUSION: A 1-year intervention to limit phosphorus absorption using dietary restriction or 2 different phosphorus binders resulted in decreased bALP suggesting improved bone turnover, but no other significant changes in biochemical or vascular parameters in patients with CKD stage 3/4. (ClinicalTrials.gov: NCT01357317).
RESUMO
BACKGROUND/AIMS: All hemodialysis (HD) patients are generally recommended to create a fistula first; but to create a mature arteriovenous fistula (AVF) can be challenging in elderly individuals. It is unclear if elderly incident HD patients derive a survival benefit from an AVF over an arteriovenous graft (AVG) or a tunneled central venous catheter (TDC). METHODS: We examined the association of vascular access type (AVF, AVG, and TDC with and without a maturing AVF/AVG at dialysis transition) at HD initiation with all-cause, cardiovascular (CV), and infection-related mortality in 46,786 US veterans using Cox models with adjustment for confounders. Effect modification by age was examined by examining associations in pre-specified age subgroups (<60, 60-<70, 70-<80, and ≥80 years old), and by including interaction terms. RESULTS: Patients numbering 8,940 (19%) started HD with an AVF, 1,090 (3%) with an AVG, 8,262 (18%) with a TDC and a maturing AVF/AVG and 28,494 (61%) with a TDC without a maturing AVF/AVG. A total of 13,303 all-cause, 4,392 CV, and 1,058 infection-related deaths were observed in the first year after HD transition. Compared to patients with AVF, those with AVG and TDC with and without maturing AVF/AVG had incrementally higher overall risk of all-cause mortality and CV mortality. Only TDC use was associated with higher infection-associated mortality. These associations were not modified by age. CONCLUSION: Although most of our patients consisted of male veterans and the results may not be generalized to the general population, the use of TDCs is associated with poor outcomes even in the most elderly incident HD patients.
Assuntos
Derivação Arteriovenosa Cirúrgica , Falência Renal Crônica/mortalidade , Falência Renal Crônica/terapia , Diálise Renal/métodos , Dispositivos de Acesso Vascular , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Cateteres de Demora , Cateteres Venosos Centrais , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estados Unidos/epidemiologia , VeteranosRESUMO
BACKGROUND: Mortality in the immediate post-hemodialysis transition period is extremely high. Many end-stage renal disease (ESRD) patients in the US start dialysis in an inpatient setting, but the characteristics of patients starting dialysis as inpatients, and the association of inpatient hemodialysis transition with mortality remain unclear. METHODS: We examined 48,261 US veterans who transitioned to hemodialysis between October 2007 and September 2011. Associations of inpatient hemodialysis starting with all-cause mortality were examined in Cox proportional hazard models, with adjustments for demographics, comorbidities, vascular access type, pre-dialysis nephrology care and medication use, and last pre-ESRD estimated glomerular filtration rate and hemoglobin. RESULTS: A total of 22,338 (46.3%) patients received the first hemodialysis treatment in an inpatient setting. Inpatient hemodialysis transition was associated with older age, presence of a tunneled catheter, higher comorbidity burden, and lack of pre-dialysis nephrology care. A total of 8,674 patients died (mortality rate 405/1,000 patient-years, 95% CI 397-413) during the first 6 months after transition to hemodialysis. The starting of inpatient vs. outpatient hemodialysis was associated with significantly higher crude all-cause mortality, but this association was attenuated after multivariable adjustments. CONCLUSIONS: Transition to hemodialysis in an inpatient setting is more common in older and sicker individuals, and in patients without pre-dialysis nephrology care and those who used a catheter for vascular access. Future studies are needed to determine if a higher proportion of patients could start hemodialysis treatment in outpatient clinics, through interventions targeting modifiable risk factors such as timely vascular access placement or earlier nephrology referrals.
Assuntos
Falência Renal Crônica/mortalidade , Falência Renal Crônica/terapia , Diálise Renal/mortalidade , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Feminino , Humanos , Pacientes Internados , Masculino , Pessoa de Meia-Idade , Nefrologia , Pacientes Ambulatoriais , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Fatores de Risco , Estados Unidos/epidemiologia , Dispositivos de Acesso Vascular , VeteranosRESUMO
Primary aldosteronism (PA) is an important and commonly unrecognized cause of secondary hypertension. Idiopathic hyperaldosteronism and aldosterone-producing adenomas account for more than 95% of PA and are characterized, respectively, by bilateral or unilateral involvement of the adrenal glands. When there is suspicion for the presence of PA, a plasma aldosterone to renin ratio should be obtained initially. Localization to determine adrenal gland involvement is done by imaging, with computerized tomography or magnetic resonance imaging. After imaging, adrenal vein sampling is done to establish treatment options. Patients with unilateral disease, who are good surgical candidates, are most appropriately managed with adrenalectomy. A biochemical cure is almost certain following adrenalectomy; however, only 30-50% of patients would show adequate blood pressure improvement. Patients with bilateral adrenal disease and those believed not to be surgical candidates are managed with mineralocorticoid antagonists.
Assuntos
Hiperaldosteronismo/diagnóstico , Gerenciamento Clínico , Humanos , Hiperaldosteronismo/complicações , Hiperaldosteronismo/terapiaRESUMO
BACKGROUND: Urinary albumin to creatinine ratio (ACR) in a single urine sample has been proposed to provide an estimate of microalbuminuria by adjusting for variability in urine concentrations. We hypothesized that adjusting the urine albumin concentration of single-void specimens for actual urine osmolality (urinary albumin to osmolality ratio [AOR]) may provide a more accurate estimate of 24-hour urine albumin excretion rates (AERs). METHODS: Patients with diabetes mellitus (DM; n = 136) had urinary concentrations of albumin, glucose, and creatinine and osmolality measured on single-void samples, and albumin levels, on 24-hour samples. Microalbuminuria is defined as an AER between 30 and 300 mg/d. RESULTS: Correlation between AOR on single-void samples and AER on 24-hour samples (r = 0.87; P < 0.001) was similar to that between ACR and AER (r = 0.88; P < 0.001). Using a cutoff value of 18.4 mg/kg/mOsm x 10(2) (18.4 mg/mmol x 10(2)) for AOR resulted in a sensitivity and specificity of 82% and 86% in detecting microalbuminuria, respectively. The area under the curve (AUC) for AOR was 0.89. Using a cutoff value of 15.0 mg/g (1.7 mg/mmol) for ACR resulted in a sensitivity and specificity of 85% and 85% in detecting microalbuminuria, respectively. The AUC for ACR was 0.90. The ability of AOR to predict AER was maintained at varying degrees of glycosuria (glucose < 100 mg/dL [<5.5 mmol/L]; r = 0.77; 100 to 750 mg/dL [5.5 to 42 mmol/L]; r = 0.85; and >750 mg/dL [>42 mmol/L]; r = 0.92). CONCLUSION: Urinary AOR correlates closely with 24-hour microalbuminuria determination, and the correlation is not appreciably affected by glycosuria. Thus, AOR can be used as an alternative test to ACR in the assessment of microalbuminuria in the population with DM.
Assuntos
Albuminas/química , Albuminúria/urina , Diabetes Mellitus Tipo 1/urina , Diabetes Mellitus Tipo 2/urina , Nefropatias Diabéticas/urina , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Análise de Variância , Área Sob a Curva , Biomarcadores/urina , Creatinina/urina , Feminino , Humanos , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Concentração OsmolarRESUMO
CONTEXT: The optimal circulating concentration of 25(OH) vitamin D is controversial. OBJECTIVE: The aim was to investigate if FGF-23 and 24,25(OH)2D can guide cholecalciferol replacement. DESIGN: Oral cholecalciferol (10,000 IU weekly) administered to subjects with 25(OH)D levels < 20 ηg/mL and eGFR > 60 mL/min/1.73 m(2) (n = 25), chronic kidney disease (CKD) (n = 27), or end stage renal disease (ESRD) (n = 14). SETTING: The study was conducted at the Veterans Affairs clinics. MAIN OUTCOME MEASURE: Serum FGF-23, PTH, 25(OH)D, 1,25(OH)2D, 24,25(OH)2D, calcium, and phosphorous concentrations, and urinary excretion of calcium and phosphorus at baseline and after 8 weeks of treatment. RESULTS: Cholecalciferol treatment increased concentrations of serum 25(OH)D by (19.3 ± 8 ηg/mL, P = .001; 12.2 ± 9 ηg/mL, P = .0001) and 24,25(OH)2D (1.14 ± 0.89 ηg/mL, P = .0024; 1.0 ± 0.72 ηg/mL P = .0002), and reduced serum PTH (-11 ± 21 pg/mL, P = .0292; -42 ± 68 pg/mL, P = .0494) in normal and CKD subjects, respectively. Cholecalciferol increased serum FGF-23 levels only in normal subjects (44 ± 57 ηg/mL, P = .01). Increments in serum 25(OH)D positively correlated with serum FGF-23 and 24,25(OH)2D and negatively correlated with PTH. In ESRD, cholecalciferol administration increased 25(OH)D by (16.6 ± 6.6 ηg/mL P ≤ .05) without changing 24,25(OH)2D, FGF-23 or PTH levels. CONCLUSION: Modest elevations of serum 25(OH)D levels after cholecalciferol treatment are sufficient to induce compensatory degradative pathways in patients with sufficient renal reserves, suggesting that optimal circulating 25(OH)D levels are approximately 20 ηg/mL. In addition, catabolism of 25(OH)D may also contribute to the low circulating vitamin D levels in CKD, since elevations of FGF-23 in CKD are associated with increased 24,25(OH)2D after cholecalciferol administration.
Assuntos
24,25-Di-Hidroxivitamina D 3/sangue , Colecalciferol/administração & dosagem , Monitoramento de Medicamentos/métodos , Fatores de Crescimento de Fibroblastos/sangue , Deficiência de Vitamina D/tratamento farmacológico , Vitamina D/análogos & derivados , 24,25-Di-Hidroxivitamina D 3/urina , Idoso , Colecalciferol/metabolismo , Fator de Crescimento de Fibroblastos 23 , Humanos , Rim/metabolismo , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Hormônio Paratireóideo/sangue , Estudos Prospectivos , Insuficiência Renal Crônica/metabolismo , Vitamina D/sangue , Vitamina D/urina , Deficiência de Vitamina D/sangue , Vitaminas/administração & dosagem , Vitaminas/metabolismoRESUMO
INTRODUCTION: To determine the prevalence of positive screens for depression and to assess quality of life (QoL) and usefulness of the brief and easily administered Patient Health Questionnaire-2 (PHQ-2) for depression screening in the chronic kidney disease (CKD) population; and to explore the relationship between depressive symptoms and markers of inflammation. METHODS: Seventy-one adult patients with estimated glomerular filtration rate <60 mL/min/1.73 m or proteinuria, but not on dialysis, were enrolled. QoL was assessed using the Short Form-36. The Center for Epidemiological Studies Depression Scale (CES-D) and PHQ-2 were used to screen for depression. Serum ferritin, albumin, C-reactive protein and hematocrit were also measured as markers of inflammation. RESULTS: The PHQ-2 and CES-D were significantly correlated (P < 0.05). Positive scores on the CES-D or PHQ-2 had significantly lower Short Form-36 scores. Mean hemoglobin values were significantly lower in patients who screened positive for depression either by CES-D (12.2 ± 1.7 versus 13.2 ± 1.7, P < 0.05) or by PHQ-2 (12 ± 1.6 versus 13.4 ± 1.6, P < 0.01). Neither PHQ-2 nor CES-D correlated with other markers of inflammation in this sample. CONCLUSION: Both the CES-D and the PHQ-2 can identify patients with CKD who need further evaluation for depression. The PHQ-2 seems to be a useful screen for depression and impaired QoL in a renal clinic setting. Patients with CKD and lower hemoglobin may be at greater risk for depression than those with normal values.
Assuntos
Depressão/diagnóstico , Falência Renal Crônica/psicologia , Qualidade de Vida/psicologia , Estudos Transversais , Depressão/etiologia , Feminino , Taxa de Filtração Glomerular , Humanos , Falência Renal Crônica/complicações , Falência Renal Crônica/terapia , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , Diálise Renal/psicologia , Inquéritos e QuestionáriosRESUMO
PURPOSE: To evaluate the safety and tissue acquisition with transjugular renal biopsy (TJRB) by using the Quick-Core method in patients who were at high risk for complications with percutaneous renal biopsy. MATERIALS AND METHODS: This was a retrospective study, and indication for the transjugular route, complications, clinical and laboratory data, and adequacy of samples were abstracted from patient records. TJRB was performed when the patient had thrombocytopenia or coagulopathy and was at high risk for bleeding from percutaneous renal biopsy. Follow-up images were available in 25 patients; nine underwent abdominal ultrasonography (US) and 17 underwent computed tomography (CT) (one patient underwent both US and CT). The hemoglobin level, prothrombin time, international normalized ratio (INR), partial thromboplastin time, platelet count, and serum creatinine level were obtained before and after biopsy, and these findings were correlated with clinical outcomes. RESULTS: Thirty-nine patients underwent 39 TJRB procedures and comprise the current study population. The procedure was technically successful in 38 of the 39 patients (97%). Twenty-four of 39 patients (63%) had a platelet count of less than or equal to 75 x 10(9)/L, 11 (29%) had an elevated INR of more than 1.4, and seven received therapeutic anticoagulation. Patients with a platelet count of less than or equal to 75 x 10(9)/L or those with an elevated INR of more than 1.4 after transfusion were not at increased risk of hematoma formation (P = not statistically significant). The mean serum creatinine level at biopsy was 283 mumol/L +/- 150. A mean of 1.8 cores +/- 1.1 were obtained, with 5.0 glomeruli +/- 3.8, 2.1 glomeruli +/- 2.8, and 2.4 glomeruli +/- 3 at light, immunofluorescence, and electron microscopy, respectively. The renal tissue was sufficient for diagnosis in 92% of patients. Major complications occurred in one patient (2.6%). Minor complications-primarily renal hematoma-occurred in 52% of the patients. Contrast medium-induced nephropathy occurred in three patients (7.8%), two of whom also had renal hematomas. CONCLUSIONS: TJRB is a relatively safe and effective diagnostic tool in high-risk patients with coagulopathy and thrombocytopenia who require renal tissue for accurate diagnosis.
Assuntos
Biópsia/métodos , Rim/patologia , Transtornos da Coagulação Sanguínea/complicações , Distribuição de Qui-Quadrado , Meios de Contraste , Extravasamento de Materiais Terapêuticos e Diagnósticos , Feminino , Humanos , Veias Jugulares , Rim/irrigação sanguínea , Masculino , Pessoa de Meia-Idade , Flebografia , Estudos Retrospectivos , Segurança , Trombocitopenia/complicaçõesRESUMO
This review summarizes the current state of knowledge about drugs, other chemical substances, and toxins on blood pressure. Many classes of drugs, such as steroids, sympathomimetic amines, immunosuppressive agents, nonsteroidal anti-inflammatory agents, antidepressants, erythropoietin, substances of abuse and other agents can induce transient or sustained hypertension, exacerbate well-controlled hypertension, antagonize the effects of antihypertensive therapy, or precipitate hypertensive emergencies. Heightened awareness on the part of the physician is important to avoid unnecessary tests in search for other etiologies, and to reduce antihypertensive medication prescriptions by eliminating contributing agents whenever possible. These agents represent an important modifiable cause of secondary or resistant hypertension.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Hipertensão/induzido quimicamente , Toxinas Biológicas/efeitos adversos , Humanos , AnamneseRESUMO
INTRODUCTION: Acetaminophen toxicity, which can lead to hepatotoxicity, is a burden on our health care system and contributes significantly to intensive care unit admissions and cost of hospitalization. The aim of our study was to determine the epidemiology of various types of acetaminophen poisoning and analyze their outcome compared with their admission characteristics. METHODS: We identified 93 consecutive patients, hospitalized for acetaminophen toxicity over a 52-month period from 1996 to 1999 in our urban county hospital. Retrospective case-control analysis was carried out using the data obtained from the medical records. RESULTS: Acetaminophen accounted for 7.5% of all cases of poisoning admitted during this period. Of the 93 patients, 80 were classified as suicidal and 13 had accidentally poisoned themselves in an attempt to relieve pain. The ratio of females to males was found to be 2:1. Of the 93 patients studied, 88 were admitted to the intensive care unit for initial 24-48 hours of monitoring. Peak acetaminophen levels were higher in the suicidal overdose group (mean 121.7 +/- 97.0 mg/l vs. 64.5 +/- 61.8 mg/l, P < 0.05) than in the accidental group. In spite of this, peak aminotransferase levels >1000 IU/l were more often seen in the latter (39% vs. 12%, P < 0.05). Hepatic coma and death were seen more often in the accidental overdose group (15% vs 0%, P < 0.05). Interestingly chronic alcohol abuse was also more frequent in the accidental overdose category (39% vs 18%, P = 0.05). DISCUSSION: Although the peak acetaminophen level in the suicidal group was significantly higher, cases of therapeutic misadventure had higher rates of morbidity and mortality. Peak acetaminophen levels correlate poorly with hepatic dysfunction, morbidity and mortality. CONCLUSION: We recommend that the patients with suicidal acetaminophen overdose, without any concomitant poisoning, can safely managed on the medical floors.
Assuntos
Acetaminofen/intoxicação , Analgésicos não Narcóticos/intoxicação , Tentativa de Suicídio/estatística & dados numéricos , Acetilcisteína/uso terapêutico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Doença Hepática Induzida por Substâncias e Drogas/epidemiologia , Doença Hepática Induzida por Substâncias e Drogas/metabolismo , Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle , Criança , Overdose de Drogas/epidemiologia , Feminino , Hospitalização , Hospitais Urbanos , Humanos , Masculino , Pessoa de Meia-Idade , New York/epidemiologia , Estudos RetrospectivosRESUMO
BACKGROUND: The albumin-to-creatinine ratio and the 24-hour urine collection to measure microalbuminuria are inconvenient and expensive. The newer rapid and less expensive dipstick methods for screening of microalbuminuria estimate only albumin and are subject to errors caused by variation in volume. We determined the relation between urine-specific gravity (Usg) and urine creatinine (Ucr) so that Ucr can be derived from Usg to correct for albumin concentration in the urine which is influenced by urine volume. METHODS: We randomly included 42 consecutive patients from the primary care clinic, and 34 patients from the diabetic clinic. RESULTS: We found that a very good correlation existed between Usg and Ucr in the 42 patients from the primary care clinic (Ucr = 11.4 x Usg -11,509, r = 0.83, p < 0.001). Patients from the diabetic clinic who had well-controlled blood sugar (n = 21) showed a similar trend (Ucr = 10.82 x Usg -10,882, r = 0.87, p < 0.001). However, this was not the case with uncontrolled diabetics (Ucr = 2.53 x Usg -2,513, r = 0.26, NS). Using simple arithmetic, we derived a simplified formula where Ucr can be predicted from Usg. Using multiple regression to incorporate the urinary glucose level by dipstick, a more generic formula was obtained for estimating urinary creatinine. CONCLUSION: Usg can be used instead of Ucr to normalize for the varied urine concentration while screening for microalbuminuria. Poorly controlled diabetics should be screened after their blood sugars are well controlled or use the more generic formula that incorporates urinary glucose. Thus, by measuring spot urine albumin and specific gravity by dipsticks one gets an easy, immediate and accurate estimation of microalbuminuria in an office setting.